| Protocol |
Title |
Status |
Contact |
| 104000 |
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma |
OPEN TO ACCRUAL |
 |
| 104110 |
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas |
OPEN TO ACCRUAL |
|
| 103736 |
A Phase 0 Master Protocol Using the CIVO Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients with Solid Tumors. |
OPEN TO ACCRUAL |
|
| 103779 |
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation |
OPEN TO ACCRUAL |
|
| 103816 |
Phase III, Open-label, Multicenter, Randomized Control Trial in Patients with r/r Mantle Cell Lymphoma to Evaluate the Efficacy, Safety and Pharmacokinetics of Glofitamab, a CD20xCD3 Bispecific Antibody |
OPEN TO ACCRUAL |
|
| 104009 |
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physicians Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma |
OPEN TO ACCRUAL |
|
| 104121 |
NRG-CC012CD: Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (Symon) |
OPEN TO ACCRUAL |
|
| 104007 |
A Phase 1b Dose Optimization Study of Sovilnesib (An Oral KIF18A Inhibitor) in Subjects with Advanced High Grade Serous Ovarian Cancer |
OPEN TO ACCRUAL |
|
| 103998 |
A Phase 1/2, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes |
OPEN TO ACCRUAL |
|
| 103968 |
A Global Pivotal Study in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of Pembrolizumab and LY3537982 vs Pembrolizumab and Placebo in those with PD-L1 50% or Pembrolizumab, Pemetrexed, Platinum Chemotherapy and LY3537982 vs Pembrolizumab, Pemetrexed, Platinum Chemotherapy and Placebo regardless of PD-L1 Expression |
OPEN TO ACCRUAL |
|
| 103958 |
Phase 3 Study of Epcoritamab, Rituximab, and Lenalidomide for First-Line Treatment of Follicular Lymphoma |
OPEN TO ACCRUAL |
|
| 104069 |
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-North America) |
OPEN TO ACCRUAL |
|
| 103864 |
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) |
OPEN TO ACCRUAL |
|
| 103981 |
A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
| 103955 |
A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications |
OPEN TO ACCRUAL |
|
| 104006 |
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination with Select Targeted Therapies in Subjects with Locally Advanced or Metastatic Solid Tumors with Oncogene Amplifications |
OPEN TO ACCRUAL |
|
| 103992 |
Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy |
OPEN TO ACCRUAL |
|
| 103713 |
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma |
OPEN TO ACCRUAL |
|
| 103989 |
A First-in-Human, Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, in Patients with Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
| 104031 |
Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma |
OPEN TO ACCRUAL |
|